April 29, 2021 in Newsroom

MOLLI 510(k) Clearance

MOLLI SURGICAL INC. ANNOUNCES FDA CLEARANCE FOR MOLLI™, A WIRE-FREE LOCALIZATION TECHNOLOGY FOR BREAST CANCER SURGERY   MOLLI provides breast cancer patients with a better experience over traditional wire and other lesion localization options; the new device helps surgeons remove lesions more efficiently with accuracy and specificity.   CHICAGO, IL, April 29, 2021 /PRWeb/ — MOLLI Surgical Inc. today announces U.S. Food and Drug Administration clearance for MOLLI™, a new wire-free localization technology for breast cancer surgery. The new technology helps radiologists mark lesions quickly and…
Read More